Research programme: Core-2 GlcNAc-T inhibitors - Inflazyme

Drug Profile

Research programme: Core-2 GlcNAc-T inhibitors - Inflazyme

Alternative Names: Core-2 GlcNAc-T inhibitors research programme - Inflazyme; Core-2 transferase inhibitors research programme - Inflazyme; IPL27 series research programme - Inflazyme; Research programme: Core-2 transferase inhibitors - Inflazyme; Research programme: IPL27 series - Inflazyme

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inflazyme Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Core 2 GlcNAc transferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Cardiovascular disorders; Diabetes mellitus; Inflammation

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Canada (PO)
  • 17 Jun 2003 GLYCODesign has been acquired by Inflazyme Pharmaceuticals
  • 05 Feb 2003 GLYCODesign has regained all rights to Core-2 inhibitors
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top